“Elderly patients with multiple myeloma strive for upfront therapy that will extend their lives,” said Karen Ferrante, M.D., Chief Medical Officer, Millennium. “Today’s VELCADE data confirmed the sustained clinical benefits, including overall survival and complete response that VELCADE provided in patients with previously untreated MM.”
Peter, a member of the MM ListServ (moderated by Beth Morgan), sent me this announcement and we were waiting for the OK to publish. Then the holidays, my excessive traveling of late, and an opportunity to actually read it, delayed me in getting up here. It is good news for the elderly patient, whose treatment options are sometimes limited by their age and overall condition to venture down some of the more aggressive paths. And of course, whenever we make breakthroughs in this group and in the high risk groups, it is good news for us all.
Thank you Peter for asking me to put this up.
“Somewhere, something incredible is waiting to be known.” – Carl Sagan
